Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Annayyaon Nov 06, 2020 2:40pm
66 Views
Post# 31852897

RE:RE:Short Report as of Oct 31

RE:RE:Short Report as of Oct 31The qualification date is four months after closing of PP so I don't think they can sell anything at a low price anytime soon. A lot can happen in progress in four months especially with aducanumab being approved now, so I am not worried.
Actuarial wrote: The shorts will come back when the SP move up to a certain level. And, the PP participants will dump their .12 shares soon. Who doesn't want an immediate 40% return and hold warrants for free?

Mole101 wrote: All gone ..;)

  • Oct 31, 2020
    Shares Shorted: 17,392 
    Net Change: -450,405
  • Oct 15, 2020
    Shares Shorted: 467,797 
    Net Change: 9,565
  • Sep 30, 2020
    Shares Shorted: 458,232 
    Net Change: -119,185
  • Sep 15, 2020
    Shares Shorted: 577,417 
    Net Change: 90,710





<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse